Trametinib
As of the edition of 20 October 2026, Trametinib is a small molecule: marketed, first approved in 2013 (US); acts on MAP2K1 and MAP2K2; US protection ends in 2030.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2016
- Kind
- Small molecule
- Brand name
- Mekinist
- First approved
- 29 May 2013 (US)
- Approvals on record
- 16 in 4 regions
- Holder of the most recent approval
- Novartis; 2 holders in all
- Registered trials
- 264, 54 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Digestive system; Lungs and airways; Blood and lymph; Hormones
US protection
US protection ends in 2030.
The last listed US drug-substance patent ends in 2030. The application that gives this date is held by Novartis.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product36 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 36 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Trametinib.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 19 | 7 | 5 | 1 |
| Phase 1 | 81 | 41 | 12 | 23 |
| Phase 2 | 146 | 48 | 59 | 29 |
| Phase 3 | 15 | 7 | 7 | 1 |
| Phase 4 | 3 | 0 | 3 | 0 |
| All trials | 264 |